# A Study to Evaluate HB0034 in Healthy Chinese Adult Participants

> **NCT06716151** · PHASE1 · RECRUITING · sponsor: **Shanghai Huaota Biopharmaceutical Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** HB0034
- **DRUG:** HB0034 matching placebo

## Key facts

- **NCT ID:** NCT06716151
- **Lead sponsor:** Shanghai Huaota Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-12-06
- **Primary completion:** 2025-11-20
- **Final completion:** 2025-11-20
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716151, "A Study to Evaluate HB0034 in Healthy Chinese Adult Participants". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06716151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*